VYNE Therapeutics Inc. Common Stock
Symbol: VYNE (NASDAQ)
0.36
▼ (-3.99%) -0.015
Company Description:
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Key Stats
- Today's Open: $0.3777
- Today's High: $0.383
- Today's Low: $0.355
- Today's Volume: 1.29M
- Yesterday Close: $0.376
- Yesterday High: $0.386299
- Yesterday Low: $0.3654
- Yesterday Volume: 1.09M
- Last Min Volume: 16
- Last Min High: $0.361
- Last Min Low: $0.361
- Last Min VWAP: $0.361
Company Profile
- Name: VYNE Therapeutics Inc. Common Stock
- Website: https://www.vynetherapeutics.com
- Listed Date: 2018-01-25
- Location: BRIDGEWATER, NJ
- Market Status: Active
- CIK Number: 0001566044
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $9.58M
- Round Lot: 100
- Outstanding Shares: 25.47M
- Asset Type: CS
RECENT FILINGS FOR VYNE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-09-12 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 8-K | View |
| 2025-07-30 | 8-K | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-05-19 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-08 | 10-Q | View |
Latest News on VYNE